Metabolic activation of irinotecan during intra-arterial chemotherapy of metastatic colorectal cancer

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3573-3578

  Czejka, Martin J ^a,c   Kiss, A ^a   Koessner, C ^a   Terkola, R ^b   Ettlinger, D ^a,c   Schueller, J ^c,d  

^a UNIVERSITY OF VIENNA   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c Austrian Society of Applied Pharmacokinetics   (Austria)

^d KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Hepatic intra arterial infusion; Irinotecan; Metabolites; Pharmacokinetics; Plasma disposition

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; HUMAN; LOW DRUG DOSE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

AGED; BIOTRANSFORMATION; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSIONS, INTRA-ARTERIAL; MIDDLE AGED; NEOPLASM METASTASIS; TIME FACTORS;

EID: 80054767978     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichel J, Alakl M, Gruia G, Awad L and Rougier P: CPT-11 combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000. (Pubitemid 30162806)
2. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 243: 905-914, 2000.
3. Michael M and Doherty MM: Tumoral drug metabolism. Overview and its implications for cancer therapy. J Clin Oncology 23: 205-229, 2005. (Pubitemid 41702640)
4. Khanna R, Morton CL and Danks MK: Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 60: 4725-4728, 2000.
5. Collins JM: Pharmacological rationale for regional drug delivery. J Clin Oncology 2: 498-504, 1984.
6. Chan R and Kerr DJ: Hepatic arterial chemotherapy for colorectal cancer liver metastases: a review of advances. Curr Opin Oncol 16: 378-384, 2004. (Pubitemid 38870045)
7. Gallagher DJ, Capanu M, Raggio G and Kemeny N: Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol 18: 1995-1999, 2007. (Pubitemid 350286238)
8. Rowland M and Tozer TN: Chapter 2: Fundamentals and terminology. In: Clinical Pharmacokinetics: Concepts and applications. Lippincott Williams & Wilkins, Baltimore (USA), pp. 17-45, 2010.
9. Van Riel JM, van Groeningen CJ, Kedde MA, Gall H, Uisink JM, Gruia G, Pinedo HM, van der Vijgh WJ and Giaccone G: Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 8: 405-412, 2002. (Pubitemid 34193957)
10. Fiorentini G, Rossi S, Dentico P, Bernadeschi P, Calcinai A, Bonechi F, Cantore M, Guadagni S and De Simone M: Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase II clinical study. Tumori 89: 382-384, 2003. (Pubitemid 37279918)
11. Cohen AD and Kemeny NE: An update on Hepatic Arterial Infusion Chemotherapy for Colorectal Cancer. The Oncologist 8: 553-566, 2003. (Pubitemid 37467371)
12. van Riel JM, van Groeningen CJ, de Greve J, Gruia G, Pinedo HM and Giaccone G: Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Ann Oncol 15(1): 59-63, 2004. (Pubitemid 38139605)
13. Pirovano M, Nasisi A, Paraboni L, Sestini S, Masseroni S, Gherardi F, Martignoni G, Meregalli M, Fornasari D, Scaglione F and Tabiadon D: Pharmacokinetics of irinotecan and SN38 after intra-arterial liver perfusion according to infusion time and circadian patient pattern in metastatic colorectal cancer. Proc ASCO 24: 18S, abstract 13557, 2006.
14. Martin RC, Robbins K, Metzger T, O'Hara R, Bosnjakovic P and Tomalty D: Hepatic intra-arterial injection of irinotecan eluting beads in unresectable colorectal liver metastatic refractory to standard systemic chemotherapy: Results of multi-institutional study. Proc ASCO, abstract No. 185, 2009.
15. Martin RC, Joshi J, Robbins K, Tomalty T, O'Hara R and Tatum C: Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, Irinotecan (DEBIRI): multi-institutional registry. J Oncol 7: 80-96, 2009.
16. Schueller J, Czejka M, Kiss A, Krexner E and Aigner K: Influence of bevacizumab on the plasma disposition of CPT-11 and its metabolites in advanced colorectal cancer patients. Proc ASCO 24, 18S, abstract 3540, 2006.
17. Czejka M, Schueller J, Hauer K, Zeleni U, Ostermann E and Eder I: Pharmacokinetics and metabolism of irinotecan (Campto®) combined with capecitabine (Xeloda®) in patients with advanced colorectal cancer (ACRC): altered disposition of the metabolites SN-38 and SN-38 glucuronide? Eur Cancer Org 12: abstract M574, 2003.